CUSTOM RNAPOLS EVALUATION: OPTIMIZE THE PRODUCTION OF YOUR mRNA
Primrose Bio’s custom Prima RNApols evaluation program is advancing the field of mRNA therapeutics and vaccines by providing access to highly performing RNA polymerases that improve efficiency, reduce costs, and enhance the quality of your mRNA production.
What are Prima RNApols?
Why Choose Prima RNApols
Evaluation Program Details
Power of Panel Case Study
What are Prima RNApols?
Prima RNApols are a proprietary collection of novel, improved and versatile RNA polymerases that produce mRNA products by in vitro transcription (IVT) of a DNA template.
Why Choose Prima RNApols
The cost and quality of mRNA manufacturing is highly dependent on the enzyme (RNApol) driving transcription of the target-dependent DNA template to mRNA drug substance in the IVT process. While there is no single RNApol that addresses all mRNA manufacturing needs, Primrose Bio has developed a panel of 20+ different RNA polymerases. Given that it is challenging to predict which RNApol will perform for different DNA templates, we screen this panel to identify enzymes that deliver high IVT performance using your materials and to the desired Key Performance Indicators (KPIs).
Higher Yield
Increasing your overall yield, as well the efficiency in utilization of key reagents (DNA template, cap analog, RNApols) delivers on your mRNA manufacturing cost targets.
Reduction in Double Stranded RNA
Up to 100x reduction in dsRNA improves quality and safety profile of your mRNA.
Higher IVT Quality
Reduces downstream processing needs, accommodates any DNA template sequence and length,and requires lower amounts of template, reducing manufacturing costs and processing time.
High Capping Efficiency
Enabling both more efficient capping and better cap analog utilization delivers on cost, quality and efficacy targets.
Compatible with Modified Nucleotides
The ability to incorporate both natural and modified nucleotides provides you with the flexibility you need in drug design.
Drug Enabling
The flexibility in accommodating even the most challenging DNA templates (such as long self-amplifying templates) rewrites what’s possible when it comes to manufacturability of mRNA drugs.
Evaluation Program Details
Screening (Weeks 1-3):
We identify 20+ enzymes tailored to your target mRNA substance and Key Performance Indicators (KPIs), such as yield, dsRNA content, integrity, and capping efficiency.
Process Optimization (Weeks 4-7):
We fine-tune IVT conditions and transfer optimized protocols for seamless integration into your applications.
Comprehensive Analytics (Weeks 6-8):
We perform best-in-class enzyme and mRNA analytics to ensure precision and quality.
Selection (Week 9-10):
Best-performing RNA polymerases are then shipped to you for further analysis, along with the resulting mRNA products.
TIMELINE
6-10 WEEKS
COST
STARTING AT $20,000
Post-Evaluation Program Steps:
- RNApol Improvement
- RNApol Manufacturing
ISO-certified RNA polymerases available in 2025 for regulatory-compliant GMP production.
Power of Panel Case Study
Total mRNA yield and integrity were measured on an Agilent Fragment Analyzer capillary electrophoresis system across all RNA sizes. The target yield was determined by quantifying the 5kb-sized peak. Integrity was calculated as the amount of the target RNA species as a percentage of total RNA. dsRNA levels were measured for equivalent amounts of total RNA synthesized in IVT reactions by immunoblotting with the J2 monoclonal antibody and quantitating spot intensities with ImageJ software.
Total mRNA yield was measured on an Agilent Fragment Analyzer capillary electrophoresis system across all RNA sizes. The target yield was determined by quantitating the 5kb-sized peak.
dsRNA levels were measured for equivalent amounts of total RNA synthesized in IVT reactions by ELISA using the SCICONSTM dsRNA ELISA Kit (based on the J2 monoclonal antibody).